Clinical development

Establishing the clinical profile of milademetan for patients with TP53 wildtype tumors.

Rain is building a pipeline that’s focused on genetically selecting the patients most likely to benefit from treatment.

Milademetan
MDM2 INHIBITOR

Milademetan is currently being investigated in liposarcomas (LPS) and a broad array of solid tumors characterized by MDM2 dependence and wildtype TP53.

Clinical Trials

indication
Phase 1
Phase 2
Phase 3
Commercial Rights
MANTRA
indication
DD* Liposarcoma
Phase 1
.
.
Phase 2
.
.
Phase 3
Enrollment Completed
EXPAND

MANTRA: Milademetan for the Treatment of Patients With Dedifferentiated (DD) Liposarcoma (LPS)

MANTRA is an ongoing Phase 3 study of milademetan in patients with DD LPS who have progressed on prior therapy.

Overview

  • Patients with DD LPS with or without a well-differentiated component
  • ≥1 Prior systemic treatment, including at least 1 prior anthracycline
  • Treatment until PD or intolerability

Endpoints

  • PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis
  • OS, ORR, DCR, DOR
  • Safety

*With or without a well-differentiated component.

DCR, disease control rate; DOR, duration of response; IV, intravenous; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; QD 3/14, once daily on days 1-3 every 14 days; Q3W, every 3 weeks.

MANTRA-2
indication
MDM2-amplified Solid Tumors
Phase 1
.
.
Phase 2
Enrolling
 
Phase 3
.
.
EXPAND

MANTRA-2: Milademetan for the Treatment of Patients With Relapsed/Refractory Advanced/Metastatic TP53  wildtype/MDM2-amplified Solid Tumors

MANTRA-2 is an ongoing Phase 2, multicenter, single-arm, open-label, basket study in patients TP53 wildtype advanced solid tumors with MDM2 gene amplification.

Overview

  • MDM2 gene CN of ≥8
  • Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus
  • Evaluable tumor types included: lung, breast, biliary, pancreatic and other select solid tumors

CN, copy number; NGS, next-generation sequencing; QD 3/14, once daily on days 1-3 every 14 days.

MANTRA-4
indication
CDKN2A Loss, TP53 WT Advanced Solid Tumors
Phase 1
Mid-2023
 
Phase 2
.
.
Phase 3
.
.
EXPAND

MANTRA-4: Milademetan in Combination With Atezolizumab for Patients With CDKN2A Loss/TP53 Wildtype Advanced Solid Tumors

MANTRA-4 is a Phase 1/2 study evaluating the safety and efficacy of milademetan + anti-PD-L1 antibody, atezolizumab, in patients with CDKN2A loss and other p53 wildtype advanced cancers.

Rain will evaluate the safety and efficacy of inhibition of the MDM2-p53 interaction with milademetan and PD-L1 inhibition with atezolizumab in patients with CDKN2A loss and WT TP53 advanced solid tumors.

Atezolizumab is utilized in this trial per a clinical supply agreement with Roche.

TP53 Wildtype Market: An Opportunity for Growth1

DD, dedifferentiated; DLT, dose-limiting toxicity; Q4W, every 4 weeks; QD 3/14, once daily on days 1-3 every 14 days; RP2D, recommended Phase 2 dose.

Reference


1. Data on file. Rain Oncology, 2023.